SCHEMBL26568181

SCHEMBL26568181

CC(C)(C)SC(=CC#N)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
ALDH1A1 P00352 5/20 0.37
NPC1 O15118 5/20 0.37
RAB9A P51151 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
HPGD P15428 3/20 0.37
MAPK1 P28482 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HIF1A Q16665 2/20 0.37
LMNA P02545 2/20 0.37
TP53 P04637 2/20 0.37
NFKB1 P19838 2/20 0.37
GMNN O75496 1/20 0.37
DRD1 P21728 1/20 0.37
DRD3 P35462 1/20 0.37
CCR2 P41597 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25506622 0.80 PDE4A (0.32) MAPTMEN1KMT2ASMN1; SMN2HTT
SCHEMBL4885770 0.77 PDE4A (0.50) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL23869688 0.75 HDAC1 (0.41) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL29483463 0.74 MAPT (0.42) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL11077132 0.74 RECQL (0.59) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL11077135 0.74 RECQL (0.59) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL24285671 0.65 GABRA1 (0.38) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL22969892 0.63 HDAC1 (0.44) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL10891997 0.63 HDAC1 (0.53) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL24855400 0.63 RECQL (0.38) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238439-A1 HER3-BINDING ANTIBODY-DRUG CONJUGATE Hummingbird Bioscience Pte. Ltd. (SG) 2024-07-18 US disclosed
US-20230330245-A1 ANTIBODY-EXATECAN CONJUGATES SYNAFFIX B.V. (NL) 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238439-A1 HER3-BINDING ANTIBODY-DRUG CONJUGATE ERBB3, EGFR, ERBB2 MAPT 882/4885MEN1 557/4885KMT2A 797/4885
US-20230330245-A1 ANTIBODY-EXATECAN CONJUGATES ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R MAPT 3039/4885MEN1 1881/4885KMT2A 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.